Daniel Reisel
Overview
Explore the profile of Daniel Reisel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
572
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glynne S, Seymour K, Reisel D, Kamal A, Newson L
Menopause
. 2025 Feb;
PMID: 39999470
Objective: The aim of this study was to explore women's experience of menopause care after breast cancer in the UK. Methods: This study is a thematic analysis of free-text comments...
2.
Glynne S, Reisel D, Kamal A, Newson L
Menopause
. 2025 Feb;
PMID: 39933042
Objectives: This study aimed to explore women's experience of menopause care after breast cancer in the UK. Methods: An online survey incorporating the validated Shared Decision Making SDM-Q-9 questionnaire was...
3.
Glynne S, Reisel D, Kamal A, Neville A, McColl L, Lewis R, et al.
Menopause
. 2024 Dec;
32(2):103-111.
PMID: 39689249
Objectives: The aims of the study are to explore the range and variation in serum estradiol concentration, and to estimate the prevalence of "poor absorption" (women using licensed estradiol doses...
4.
Kamal A, Kamara S, Khasriya R, Elneil S, Newson L, Reisel D
Maturitas
. 2024 Jul;
187:108058.
PMID: 38959753
Female genital mutilation is widely recognised as a practice that causes grave, permanent damage to the genital anatomy and function. The literature has documented its impact on physical, sexual, emotional,...
5.
Haran S, Chindera K, Sabry M, Wilkinson N, Arora R, Zubiak A, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539519
Background: Tissue-specificity for fimbrial fallopian tube ovarian carcinogenesis remains largely unknown in mutation carriers. We aimed to assess the cell autonomous and cell-nonautonomous implications of a germline mutation in the...
6.
Evans I, Reisel D, Jones A, Bajrami A, Nijjar S, Solangon S, et al.
Lancet Oncol
. 2023 Nov;
24(12):1375-1386.
PMID: 37944542
Background: To detect uterine cancer, simpler and more specific index tests are needed to triage women with abnormal uterine bleeding to a reference histology test. We aimed to compare the...
7.
Herzog C, Jones A, Evans I, Reisel D, Olaitan A, Doufekas K, et al.
Int J Cancer
. 2023 Oct;
154(4):679-691.
PMID: 37861205
Analysis of cell-free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D...
8.
Barrett J, Jones A, Evans I, Herzog C, Reisel D, Olaitan A, et al.
Int J Cancer
. 2022 Dec;
152(9):1977-1988.
PMID: 36533702
The incidence of endometrial cancer is rising. Measures to identify women at risk and to detect endometrial cancer earlier are required to reduce the morbidity triggered by the aggressive treatment...
9.
Herzog C, Marin F, Jones A, Evans I, Reisel D, Redl E, et al.
J Clin Oncol
. 2022 Aug;
40(33):3828-3838.
PMID: 36001862
Purpose: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a...
10.
Bartlett T, Evans I, Jones A, Barrett J, Haran S, Reisel D, et al.
Genome Med
. 2022 Jul;
14(1):76.
PMID: 35854342
No abstract available.